Lung Cancer | Specialty

Expert Addresses Global Disparities in Lung Cancer, Efforts to Bridge the Gap

March 8th 2018

Gilberto Lopes, MD, discusses the global disparities occurring in lung cancer care and some of the steps that are being taken to better serve patients with the available and emerging therapeutic approaches.

Dr. Spigel on the Rationale Behind the PACIFIC Trial

March 8th 2018

David Spigel, MD, chief scientific officer, director, Lung Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses the rationale behind the design of PACIFIC, a trial that investigated the use of durvalumab (Imfinzi) in patients with locally advanced, unresectable stage III lung cancer.

Brahmer Highlights Latest on Immunotherapy and Other Lung Cancer Advances

March 8th 2018

Julie R. Brahmer, MD, discusses first-line immunotherapy, targeted therapies for molecularly driven tumors, and recently released guidelines for the treatment of patients with lung cancer.

Dr. Goldberg Discusses Resistance to EGFR TKI Therapy in NSCLC

March 8th 2018

Sarah B. Goldberg, MD, MPH, an assistant professor of medicine at the Yale School of Medicine and Yale Cancer Center, discusses testing for and treating resistance to EGFR tyrosine kinase inhibitor (TKI) therapy in non–small cell lung cancer.

Goldberg Gives Expert Insight on EGFR-TKI Resistant NSCLC

March 7th 2018

Sarah B. Goldberg, MD, discusses testing for and treating resistance to EGFR TKI therapy in non-small cell lung cancer.

Schwartzberg Highlights Existing and Emerging Targets in NSCLC

March 6th 2018

Lee Schwartzberg, MD, discusses the importance of next-generation sequencing and the state of biomarker development in the management of patients with NSCLC.

FDA Approves 4-Week Nivolumab Dosing Schedule

March 6th 2018

The FDA has approved a supplemental biologics license application adding a 4-week dosing schedule for nivolumab across several of the PD-1 inhibitor’s indications.

Spigel Reflects on Recent Immunotherapy Success in Stage III NSCLC

March 2nd 2018

David R. Spigel, MD, discusses the status of immunotherapy in locally advanced NSCLC and highlights recent milestones.

Levy Lends Insight on Pivotal NSCLC Trials

March 2nd 2018

Benjamin P. Levy, MD, highlights trials that continue to shape the treatment landscape for patients with lung cancer.

Expert Calls for Cross-Communication in NSCLC Treatment Decisions

March 1st 2018

Shirley Michelle Shiller, DO, discusses the application of biomarkers and the importance of educating practitioners on treatment advancements in NSCLC.

Optimizing Immunotherapy in Lung Cancer

March 1st 2018

Claude Denham, MD, discusses the challenges with immunotherapy in NSCLC cancer, as well as the promise of combination therapy.

Pearls of Wisdom for the Field of NSCLC

March 1st 2018

Sequencing Therapies for ALK-Rearranged NSCLC

March 1st 2018

New Standard of Care for ALK-Rearranged NSCLC

March 1st 2018

Ongoing Research in EGFR+ NSCLC

March 1st 2018

Treatment of EGFR+ NSCLC Brain Metastases

March 1st 2018

New Standard for Treating Stage 4 EGFR+ NSCLC

March 1st 2018

Biomarkers for Selection of Immuno-Oncology Agents in NSCLC

March 1st 2018

Dual Checkpoint Inhibitor Therapy for NSCLC

March 1st 2018

Quadruple Therapy for Newly Diagnosed NSCLC

March 1st 2018